Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Brunswick

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Current Protocols in Immunology|April 25, 2008
Proliferative assays for B cell functionJames J Mond, Mark Brunswick
Medicine in Drug Discovery|April 15, 2020
Novel decoy cellular vaccine strategy utilizing transgenic antigen-expressing cells as immune presenter and adjuvant in vaccine prototype against SARS-CoV-2 virusHenry Ji, Ying Yan, Beibei Ding, et al.
Med (New York, N.Y.)|February 10, 2024
Olgotrelvir, a dual inhibitor of SARS-CoV-2 M<sup>pro</sup> and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19Long Mao, Namir Shaabani, Xiaoying Zhang, et al.
Scientific Reports|September 15, 2022
Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodiesXia Cao, Junki Maruyama, Heyue Zhou, et al.
Med (New York, N.Y.)|January 5, 2024
Olgotrelvir, a dual inhibitor of SARS-CoV-2 M<sup>pro</sup> and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19Long Mao, Namir Shaabani, Xiaoying Zhang, et al.
NEJM Evidence|May 28, 2024
Olgotrelvir as a Single-Agent Treatment of Nonhospitalized Patients with Covid-19Rongmeng Jiang, Bing Han, Wanhong Xu, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Current Protocols in Immunology|April 25, 2008
Proliferative assays for B cell functionJames J Mond, Mark Brunswick
Medicine in Drug Discovery|April 15, 2020
Novel decoy cellular vaccine strategy utilizing transgenic antigen-expressing cells as immune presenter and adjuvant in vaccine prototype against SARS-CoV-2 virusHenry Ji, Ying Yan, Beibei Ding, et al.
Med (New York, N.Y.)|February 10, 2024
Olgotrelvir, a dual inhibitor of SARS-CoV-2 M<sup>pro</sup> and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19Long Mao, Namir Shaabani, Xiaoying Zhang, et al.
Scientific Reports|September 15, 2022
Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodiesXia Cao, Junki Maruyama, Heyue Zhou, et al.
Med (New York, N.Y.)|January 5, 2024
Olgotrelvir, a dual inhibitor of SARS-CoV-2 M<sup>pro</sup> and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19Long Mao, Namir Shaabani, Xiaoying Zhang, et al.
NEJM Evidence|May 28, 2024
Olgotrelvir as a Single-Agent Treatment of Nonhospitalized Patients with Covid-19Rongmeng Jiang, Bing Han, Wanhong Xu, et al.
Pageof 1